SGRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Surgery Partners Inc (SGRY) is not a strong buy for a beginner, long-term investor at this moment. The company is facing significant financial and operational challenges, reflected in its recent earnings miss, declining margins, and negative net income. While hedge funds are buying heavily, insider selling and weak financial performance raise concerns. The technical indicators suggest the stock is overbought, and no strong trading signals are present. Thus, it is better to hold off on investing in SGRY until there is a clearer sign of recovery or improvement in fundamentals.
The MACD histogram is positive at 0.233 and expanding, indicating bullish momentum. However, the RSI is at 85.42, signaling the stock is overbought. Moving averages are converging, suggesting a lack of strong directional momentum. Key resistance levels are at R1: 13.318 and R2: 13.686, with support at S1: 12.126 and S2: 11.758.
Hedge funds are significantly increasing their buying activity, with a 682.35% increase in the last quarter. The stock has a 50% chance of gaining 3.85% in the next week based on historical patterns.
Insiders are selling heavily, with a 258.25% increase in selling activity over the last month. Analysts have significantly lowered price targets across the board due to disappointing Q4 results and operational challenges. The stock is overbought as per RSI, and no recent news or event-driven catalysts are present to support a strong upward move.
In 2025/Q4, revenue increased by 2.38% YoY to $885M, but net income dropped by -86.18% YoY to -$15M. EPS also declined by -86.05% YoY to -0.12, and gross margin fell by -25.50% YoY to 17.21%. The company's financial performance indicates significant pressure on profitability and operational efficiency.
Analysts have lowered price targets significantly, with the highest target now at $24 (down from $30) and the lowest at $14. Despite this, most analysts maintain a Buy or Outperform rating, citing potential for improvement in 2026 and M&A-driven growth. However, near-term challenges such as cost pressures, payer mix issues, and disappointing guidance weigh heavily on sentiment.
